Handelsbanken Fonder Ab Nektar Therapeutics Transaction History

Handelsbanken Fonder Ab

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$3.17 - $6.17 $65,302 - $127,102	-20,600 Reduced 59.65%	13,934 $53,000
Q2 2020 Aug 13, 2020	BUY	$16.86 - $23.44 $582,243 - $809,476	34,534 New	34,534 $800,000
Q3 2019 Oct 31, 2019	SELL	$16.91 - $36.27 $998,248 - $2.14 Million	-59,033 Closed	0 $0
Q2 2019 Jul 12, 2019	SELL	$31.0 - $36.3 $502,200 - $588,060	-16,200 Reduced 21.53%	59,033 $2.1 Million
Q1 2019 May 10, 2019	BUY	$31.58 - $46.35 $353,696 - $519,120	11,200 Added 17.49%	75,233 $2.53 Million
Q4 2018 Jan 31, 2019	BUY	$30.43 - $56.65 $411,809 - $766,644	13,533 Added 26.8%	64,033 $2.11 Million
Q3 2018 Oct 23, 2018	BUY	$46.46 - $68.49 $2.35 Million - $3.46 Million	50,500 New	50,500 $3.08 Million
Q3 2018 Oct 19, 2018	SELL	$46.46 - $68.49 $1.42 Million - $2.09 Million	-30,500 Closed	0 $0
Q2 2018 Jul 11, 2018	SELL	$46.25 - $104.45 $809,375 - $1.83 Million	-17,500 Reduced 36.46%	30,500 $1.49 Million
Q1 2018 May 18, 2018	SELL	$57.4 - $108.44 $1.21 Million - $2.28 Million	-21,000 Reduced 30.43%	48,000 $5.1 Million
Q4 2017 Feb 21, 2018	BUY	$23.02 - $60.5 $1.59 Million - $4.17 Million	69,000	69,000 $4.12 Million

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.